IDH305 is a potent and selective mutant IDH1 inhibitor that has demonstrated brain exposure in rodents, D2-HG reduction, and efficacy in a patient-derived IDH1 mutant xenograft tumor model (121). The gene discussed is IDH1; the disease is neoplasm.